艾曲泊帕治疗骨髓增生异常综合征血小板减少症：有反应与无反应患者之间的差异——一项初步研究 - Suppr | 超能文献

相似文献

1

Eltrombopag treatment for thrombocytopenia in myelodysplastic syndromes: differences between responding and non-responding patients-a pilot study.艾曲泊帕治疗骨髓增生异常综合征血小板减少症：有反应与无反应患者之间的差异——一项初步研究

Intern Emerg Med. 2025 Jun;20(4):1283-1286. doi: 10.1007/s11739-024-03804-3. Epub 2024 Oct 31.

2

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.艾曲泊帕与安慰剂治疗血小板减少的低危骨髓增生异常综合征（EQoL-MDS）：一项单盲、随机、对照、2期优效性试验的1期结果

Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.

3

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.艾曲泊帕与安慰剂治疗晚期骨髓增生异常综合征或急性髓系白血病患者血小板减少症的安全性和耐受性：一项多中心、随机、安慰剂对照、双盲1/2期试验。

Lancet Haematol. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1.

4

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.一项关于血小板生成素受体激动剂艾曲泊帕在接受阿扎胞苷治疗的骨髓增生异常综合征患者中的I期剂量探索性安全性试验。

Eur J Haematol. 2014 Nov;93(5):439-45. doi: 10.1111/ejh.12383. Epub 2014 Jun 14.

5

Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.艾曲泊帕用于晚期骨髓增生异常综合征或急性髓系白血病及严重血小板减少症（ASPIRE）：一项随机、安慰剂对照的2期试验。

Lancet Haematol. 2018 Jan;5(1):e34-e43. doi: 10.1016/S2352-3026(17)30228-4. Epub 2017 Dec 11.

6

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).依鲁替尼治疗血小板减少性低危骨髓增生异常综合征的疗效：一项 II 期、随机、安慰剂对照临床试验（EQOL-MDS）的中期结果。

J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9.

7

Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.Eltrombopag 用于治疗骨髓增生异常综合征或急性髓系白血病伴严重血小板减少的长期安全性和疗效：ASPIRE 扩展研究的结果。

Acta Haematol. 2023;146(5):373-378. doi: 10.1159/000531146. Epub 2023 May 19.

8

Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study).高危骨髓增生异常综合征和相关疾病患者的艾曲泊帕和阿扎胞苷的 Ib 期研究（ELASTIC 研究）。

Br J Haematol. 2022 Oct;199(2):222-229. doi: 10.1111/bjh.18389. Epub 2022 Aug 2.

9

Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial.骨髓增生异常综合征合并血小板减少症患者基线基因突变情况及艾曲泊帕和阿扎胞苷治疗结果的下一代测序：来自SUPPORT临床试验的数据

EJHaem. 2023 May 22;4(3):876-881. doi: 10.1002/jha2.694. eCollection 2023 Aug.

10

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.阿扎胞苷联合或不联合艾曲泊帕治疗伴有血小板减少的中高危骨髓增生异常综合征的一线治疗。

Blood. 2018 Dec 20;132(25):2629-2638. doi: 10.1182/blood-2018-06-855221. Epub 2018 Oct 10.

本文引用的文献

1

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).依鲁替尼治疗血小板减少性低危骨髓增生异常综合征的疗效：一项 II 期、随机、安慰剂对照临床试验（EQOL-MDS）的中期结果。

J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9.

2

Immune Thrombocytopenia.免疫性血小板减少症

N Engl J Med. 2019 Sep 5;381(10):945-955. doi: 10.1056/NEJMcp1810479.

3

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.